EFTA00953704.pdf

From: "Lang, Caroline" cj To: Jeffrey Epstein <jeevaeation(kgmail.com> Subject: FW: Divers Date: Wed, 13 Feb 2013 15:29:11 +0000 Attachments: OSE_Corp_Pres_Feb_2013.pdf ( awhile I ang lel From: Etienne Binant [mailto Sent: mercredi 13 fevrier 2013 16:28 To: Lang, Caroline Subject: RE: Divers Hey Here is the corporate presentation Terms are: 60 M€ pre-money valuation, 5 M€ to be invested to pre pare pre IPO round+ 1 board membership+ usual shareholder's agreement Let me know if you want more E From: Jeffrey Epstein [mailto:[email protected]] Sent: mercredi 13 fevrier 2013 16:01 To: Lang, Caroline Subject: Re: FW: Divers no buisness terms that i see On Wed, Feb 13, 2013 at 10:12 AM, Lang, Caroline < > wrote: Hi Jeffrey, I am sure you remember Sebastien who runs the company of the designer Andree Putmann. He lives with Etienne Binant. Last time you were in town I wanted us to have dinner with them, but then you had to leave. Etienne is a business man himself. Normally he raises funds for science. He believes that his last venture may interest you, so I am forwarding it to you. See his email below and attached as well Big kiss Caroline Caroline Lang EFTA00953704 From: Etienne Binant [mailto Sent: mardi 12 février 2013 22:41 To: Lang, Caroline Subject: RE: Divers Dear Caroline, Thank you for taking the time to answer. OSE Pharma, the company I briefly talked to you about, is a European (swiss and French) company created mostly based on assets acquired from Takeda (spin-off). Mostly, it is the take-over of assets from the former company Epimunne, that was listed on NASDAQ. Emile Loria and Dominique Costantini, both MDs, are the co-founders of the company. Emile Loria is an international class scientist, formerly at Epimunne, who engineered the spin-off from Takeda. Dominique Costantini, in the capacity of CEO of BioAlliance Pharma, a company she founded in the 90's, has raised close to 200 M$ on public markets. Anyways, around 100 M$ were invested in order to create OSE Pharma's current assets, and 10 years of work. Nowadays, this is a late stage company with FDA approved orphan drug clearance, patents granted in Europe and in the USA. The company is beginining phase III for its lung cancer drug programme, and Phase II for cystic fibrosis cure. Dominique Costantini knows she can float the company through an IPO within the next 18 months, she has a strong track record with that. She has funded the company with her money and her boards' (no Venture capital) and would prefer to raise 5 M€ to prepare for the IPO with private investors. Please feel free to pass this along if you think this is interesting enough. I'll be in NYC next week, by the way Cheers and big kisses to the girls! xoxo E From: To: Date: Tue, 12 Feb 2013 17:42:42 +0100 Subject: RE: Divers Salut Etienne, Oui ! je suis toujours intéressée par le yoga ! Ton dossier peut être attirant pour Jeffrey. Si tu veux, envoie le moi avec un petit mot en anglais et je lui transfère en te mettant en cc? Bisous Caroline From: Etienne Binant [mailto Sent: lundi II février 2013 23:04 To: Lang, Caroline Subject: Divers Cara Caroline, Comment vas-tu? Est-ce que tu te sens un peu mieux? Es-tu toujours intéressée par le yoga? EFTA00953705 Je travaille sur un dossier fres interessant de biotechnologies, une phase III (bien avanc€e) de lutte contre le cancer du poumon et la mucovisddose, les deux fondateurs ont déjà coles plusieurs societes quelques centaines de millions en bourse, ils ont rachete les actifs d'un gros laboratoire pharma et its preparent rear& en bourse (IPO) de la societe. Nous rassemblons un tour de table de quelques "high net worth individuals". Crois-tu que cela puisse interesser Jeff E? II est connu pour s'interesser aux investissements techno, et it s'agit d'un sujet qui allie possibilite de belles sorties (I3lovex, etc se sont valorises plus de 600 M$ en bourse) et preoccupations non lucratives Dis moi, je t'envoie un dossier Baci Etienne *********************************************************** The information contained In this communication is confidential, may be attorney-dient privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of Jeffrey Epstein Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by retum e-mail or by e-mail to [email protected] and destroy this communication and all copies thereof, Including all attachments. copyright -all rights reserved EFTA00953706